Loading...
Compass Ratings
The Alexandria Compass
930+ stocks rated across NYSE & NASDAQ. Every stock scored 1–100 blending quantitative financials with qualitative moat, catalyst, and theme analysis — updated daily.
Theme Navigation
Browse Alexandria's ratings universe through its major market themes.
Coverage Universe
930 rated stocks organized through the Compass framework.
Updated daily
| Logo | Tier | Category | Growth | P/E | ||||
|---|---|---|---|---|---|---|---|---|
 | LLY | Eli Lilly and Company | 92 | True North | Biotech & Genomics | $909B | +55.5% | 36.2x |
 | ALNY | Alnylam Pharmaceuticals | 90 | True North | Biotech & Genomics | $40B | +96.4% | 75.2x |
C | CAI | Caris Life Sciences, Inc. | 90 | True North | Biotech & Genomics | $4B | +78.8% | - |
 | ARGX | argenx SE | 90 | True North | Biotech & Genomics | $50B | +62.6% | 35.7x |
B | BLLN | BillionToOne, Inc. | 90 | True North | Biotech & Genomics | $4B | +83.8% | 154.4x |
C | CGON | CG Oncology, Inc. | 90 | True North | Biotech & Genomics | $6B | +1982.7% | - |
A | AUPH | Aurinia Pharmaceuticals Inc. | 90 | True North | Biotech & Genomics | $2B | +24.4% | 7.4x |
 | CRSP | CRISPR Therapeutics | 89 | True North | Biotech & Genomics | $5B | +68.6% | - |
 | DXCM | DexCom Inc. | 89 | True North | Biotech & Genomics | $28B | +15.0% | 30.7x |
 | BEAM | Beam Therapeutics | 89 | True North | Biotech & Genomics | $3B | +324.9% | - |
T | TGTX | TG Therapeutics, Inc. | 88 | True North | Biotech & Genomics | $6B | +69.6% | 13.9x |
A | ASND | Ascendis Pharma A/S | 88 | True North | Biotech & Genomics | $15B | +144.3% | 27.3x |
A | ARQT | Arcutis Biotherapeutics, Inc. | 88 | True North | Biotech & Genomics | $3B | +60.1% | - |
 | SYK | Stryker Corporation | 85 | True North | Biotech & Genomics | $123B | +2.6% | 37.2x |
O | OGN | Organon & Co. | 85 | True North | Biotech & Genomics | $4B | -3.5% | 14.5x |
 | EXAS | Exact Sciences | 83 | True North | Biotech & Genomics | $20B | +23.1% | - |
S | SEPN | Septerna, Inc. | 82 | True North | Biotech & Genomics | $1B | +12011.0% | - |
P | PHAT | Phathom Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $947M | +104.4% | - |
B | BIOA | BioAge Labs, Inc. | 82 | True North | Biotech & Genomics | $716M | +91.0% | - |
X | XFOR | X4 Pharmaceuticals, Inc. | 82 | True North | Biotech & Genomics | $356M | -90.6% | - |
 | REGN | Regeneron Pharmaceuticals | 82 | True North | Biotech & Genomics | $68B | +19.0% | 15.9x |
C | CCCC | C4 Therapeutics, Inc. | 82 | True North | Biotech & Genomics | $363M | -15.0% | - |
P | PRTC | PureTech Health plc | 82 | True North | Biotech & Genomics | $424M | -38.2% | 9.2x |
N | NUVB | Nuvation Bio Inc. | 82 | True North | Biotech & Genomics | $2B | +2598.7% | - |
 | RXRX | Recursion Pharmaceuticals | 82 | True North | Biotech & Genomics | $2B | -56.1% | - |
M | MESO | Mesoblast Limited | 82 | True North | Biotech & Genomics | $2B | +1526.8% | - |
 | DNA | Ginkgo Bioworks | 82 | True North | Biotech & Genomics | $504M | -49.1% | - |
C | CLOV | Clover Health Investments, Corp. | 82 | True North | Biotech & Genomics | $2B | +62.0% | - |
 | VRTX | Vertex Pharmaceuticals | 82 | True North | Biotech & Genomics | $109B | +7.8% | 25.6x |
Z | ZYME | Zymeworks Inc. | 82 | True North | Biotech & Genomics | $2B | -91.1% | - |
B | BWAY | BrainsWay Ltd. | 82 | True North | Biotech & Genomics | $612M | +34.6% | 69.5x |
Z | ZVRA | Zevra Therapeutics, Inc. | 82 | True North | Biotech & Genomics | $605M | +77.5% | 5.1x |
G | GLPG | Lakefront Biotherapeutics NV | 82 | True North | Biotech & Genomics | $2B | -91.4% | 3.2x |
C | CARL | Carlsmed, Inc. | 82 | True North | Biotech & Genomics | $320M | +58.2% | - |
M | MOVE | Corvex Inc. | 82 | True North | Biotech & Genomics | $2B | +60.0% | - |
B | BBNX | Beta Bionics, Inc. | 82 | True North | Biotech & Genomics | $451M | +56.6% | - |
A | ASTH | Astrana Health, Inc. | 82 | True North | Biotech & Genomics | $2B | +55.6% | 63.5x |
A | AVAH | Aveanna Healthcare Holdings Inc. | 82 | True North | Biotech & Genomics | $2B | +15.9% | 6.3x |
C | CDNA | CareDx, Inc. | 82 | True North | Biotech & Genomics | $1B | +39.0% | - |
B | BCYC | Bicycle Therapeutics plc | 82 | True North | Biotech & Genomics | $309M | +1193.3% | - |
R | RIGL | Rigel Pharmaceuticals, Inc. | 81 | True North | Biotech & Genomics | $533M | +10.3% | 1.5x |
T | TMDX | TransMedics Group, Inc. | 81 | True North | Biotech & Genomics | $2B | +21.2% | 15.6x |
B | BBIO | BridgeBio Pharma, Inc. | 81 | True North | Biotech & Genomics | $13B | +66.8% | - |
S | SRTA | Strata Critical Medical, Inc. | 80 | True North | Biotech & Genomics | $479M | +87.4% | - |
E | ELV | Elevance Health, Inc. | 78 | True North | Biotech & Genomics | $86B | +2.6% | 16.8x |
T | TNGX | Tango Therapeutics, Inc. | 78 | True North | Biotech & Genomics | $3B | +363.6% | - |
M | MD | Pediatrix Medical Group, Inc. | 78 | True North | Biotech & Genomics | $2B | +3.9% | 10.9x |
P | PACS | PACS Group, Inc. | 77 | Favorable | Biotech & Genomics | $6B | +11.2% | 23.9x |
B | BLFS | BioLife Solutions, Inc. | 77 | Favorable | Biotech & Genomics | $1B | +24.7% | - |
B | BVS | Bioventus Inc. | 77 | Favorable | Biotech & Genomics | $741M | +6.6% | 26.7x |